Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 166

Sort by

Sort Order Select

Journal Articles

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Marco Rossi, MD, Emanuela Altomare, PhD, Cirino Botta, MD, Maria Eugenia Gallo Cantafio, Marco Gaspari, Domenico Taverna, Sarvide Sarai, Daniele Caracciolo, MD, Paola Critelli, MD, Francesco Conforti, Maria Teresa Di Martino, PhD, Bruno Paiva, PhD, Pierosandro Tagliaferri, MD, Pierfrancesco Tassone, MD

Blood (2019) 134 (Supplement_1): 505.

https://doi.org/10.1182/blood-2019-122429

Published: 2019

Journal Articles

Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor

Ken Morita, MD PhD, Shuning He, PhD, Radosław P. Nowak, PhD, Jinhua Wang, PhD, Nathanael Gray, PhD, Eric S. Fischer, PhD, A. Thomas Look, MD

Blood (2019) 134 (Supplement_1): 406.

https://doi.org/10.1182/blood-2019-123573

Published: 2019

Journal Articles

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

Andrea Tomirotti, PhD, Giuseppe Merlino, Alessio Fiascarelli, PhD, Simone Baldini, MD, Alessia Tagliavini, Elisa Borella, Milena Mazan, PhD, Krzysztof Brzózka, PhD, Alessandro Bressan, Andrea Pellacani, PhD MD, Massimiliano Salerno, Monica Binaschi, PhD, Daniela Bellarosa

Blood (2019) 134 (Supplement_1): 5087.

https://doi.org/10.1182/blood-2019-124800

Published: 2019

Journal Articles

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Lai N Chan, PhD, Mark A. Murakami, MDMA,MMSc, Rebecca Caesar, Christian Hurtz, PhD, Kohei Kume, PhD, Teresa Sadras, PhD, Seyedmehdi Shojaee, PhD, Petri Pölönen, MSc, Amol Ugale, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD, Arun P. Wiita, MD PhD, Shai Izraeli, MD, David M Weinstock, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3944.

https://doi.org/10.1182/blood-2019-130774

Published: 2019

Journal Articles

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Timothy S. Pardee, MD PhD, Kris C Wood, PhD, Kevin H Lin, BS, Justine Rutter, PhD, Mariaelena Pierobon, MD, Emanuel Petricoin, PhD, Susan Lyerly, P.A.-C., Sarah Dralle, NP, Megan Manuel, NP, Leslie Renee Ellis, MD, Dianna S. Howard, MD, Rupali Bhave, MD, Bayard L Powell, MD

Blood (2019) 134 (Supplement_1): 1388.

https://doi.org/10.1182/blood-2019-129413

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity

Carlotta Abbà, MSc, Rita Campanelli, Paolo Catarsi, Laura Villani, Vittorio Abbonante, PhD, Christian Andrea Di Buduo, PhD, Melania Antonietta Sesta, Vittorio Rosti, MD, Giovanni Barosi, MD, Margherita Massa

Blood (2018) 132 (Supplement 1): 4337.

https://doi.org/10.1182/blood-2018-99-114684

Published: 2018

Journal Articles

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

Mario Scarpa, PhD, Shivani Kapoor, MS, Danilo Perrotti, MD PhD, Maria R. Baer, MD

Blood (2018) 132 (Supplement 1): 3951.

https://doi.org/10.1182/blood-2018-99-117609

Published: 2018

Journal Articles

Tecfidera Modulates Activation of Malignant B-Cells: Correlative Analysis from a Phase 1 Clinical Trial in Patients with Chronic Lymphocytic Leukemia

Christina Wu, PhD, Emanuela M. Ghia, PhD, Fitzgerald Lao, Minya Pu, PhD, Karen Messer, PhD, Laura Z. Rassenti, PhD, Thomas J. Kipps, MD PhD, Dennis A. Carson, MD, Michael Y. Choi, MD

Blood (2018) 132 (Supplement 1): 3143.

https://doi.org/10.1182/blood-2018-99-119292

Published: 2018

Journal Articles

MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia

Blood (2018) 132 (Supplement 1): 2627.

https://doi.org/10.1182/blood-2018-99-116256

Published: 2018

Journal Articles

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

Sarah K. Tasian, MD, Albert Assad, MD, Deborah S Hunter, PhD, Yining Du, PhD, Mignon L. Loh, MD

Blood (2018) 132 (Supplement 1): 555.

https://doi.org/10.1182/blood-2018-99-110221

Published: 2018

Journal Articles

Interferon-γ Induces Distinct mRNA and Protein Profiles in Acute and Chronic Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Rhonda Meredith, BSc, Paul Martin Ross, BSc, BA, Sarah Wagner, BSc MSc, Stephen Reeder, BSc, Gokhan Demirkan, PhD, Jamie R. Kuhar, PhD, Graham R. Ball, PhD, A. Graham Pockley, PhD, Sergio Rutella, MDPhDFRCPath

Blood (2017) 130 (Supplement 1): 3945.

https://doi.org/10.1182/blood.V130.Suppl_1.3945.3945

Published: 2017

Journal Articles

Enhanced Efficacy of the SYK Inhibitor Entospletinib and Chemotherapy in Infant Acute Lymphoblastic Leukemia

Joseph Patrick Loftus, BS, Anella Yahiaoui, BS, Feng Shen, MDPhD, David Lopez, Igor Mikaelian, DVM, Patrick A Brown, MD, Stacey Tannheimer, PhD, Ann Forslund, PhD, Sarah K Tasian, MD

Blood (2017) 130 (Supplement 1): 2611.

https://doi.org/10.1182/blood.V130.Suppl_1.2611.2611

Published: 2017

Journal Articles

Integrated Phosphoproteomic and N-Glycoproteomic Landscape of Cutaneous T-Cell Lymphoma Reveals Distinctive Pathogenetic Insights and Therapeutic Vulnerabilities

John Simon Van Arnam, MD MS, Delphine C. M. Rolland, PharmD, PhD, Kojo S. J. Elenitoba-Johnson, MD, Megan S. Lim, MDPhD, Özlem Önder, PhD, Nathanael G. Bailey, MD, David Bahler, MD

Blood (2017) 130 (Supplement 1): 2763.

https://doi.org/10.1182/blood.V130.Suppl_1.2763.2763

Published: 2017

Journal Articles

CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

Sudhakiranmayi Kuravi, M.S., Elizabeth Parrott, M.A., Siddhartha Ganguly, MD, Anusha Vallurupalli, MD, Yogenthiran Saunthararajah, MD, Brian S Blagg, PhD, Jensen Roy, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2017) 130 (Supplement 1): 2758.

https://doi.org/10.1182/blood.V130.Suppl_1.2758.2758

Published: 2017

Journal Articles

Mutation-Specific Signaling Profiles and Therapeutic Vulnerabilities of Induced Pluripotent Stem Cell Models of Juvenile Myelomonocytic Leukemia

Sarah K Tasian, MD, Jessica A Casas, MD MPH, David Posocco, Shilpa Gandre-Babbe, Alyssa Gagne, Ge Liang, Mignon L. Loh, MD, Mitchell J Weiss, MD PhD, Deborah L French, PhD, Stella T Chou, MD

Blood (2017) 130 (Supplement 1): 1678.

https://doi.org/10.1182/blood.V130.Suppl_1.1678.1678

Published: 2017

Journal Articles

Characterization of Kinase Activity By Phosphoproteomics in Myeloid Cell Lines for Identification of Driving Oncogenic Pathways

Mahmoud Hallal, Manfred Heller, PhD, Rémy Bruggmann, PhD, Ramanjaneyulu Allam, PhD MSc, BSc, Raphael Jeancourt, PhD, Elisabeth Oppliger Leibundgut, PharmD, Cédric Simillion, PhD, Nicolas Bonadies, MD

Blood (2017) 130 (Supplement 1): 2515.

https://doi.org/10.1182/blood.V130.Suppl_1.2515.2515

Published: 2017

Journal Articles

DNA Damaging Agents Cause a Sub-Cellular Re-Localisation of Nucleophosmin in an npm1 Mutated Acute Myeloid Leukemia (AML) Cell Line and in Primary AML Cells Carrying an npm1 Mutation

Graham D. Bailey, PhD, Asma Akhtar, BSc, Nigel H. Russell, Claire Seedhouse, PhD

Blood (2017) 130 (Supplement 1): 1251.

https://doi.org/10.1182/blood.V130.Suppl_1.1251.1251

Published: 2017

Journal Articles

Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS -Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109

Kira Gritsman, MD PhD, Robert P. Hasserjian, MD, Taneisha Sinclair, David M. Weinstock, MD, Britta Will, PhD, Ulrich Steidl, MD PhD, Karen K. Ballen, MD, Amir T. Fathi, MD, Amit Verma, MD, Dejan Juric, MD, Philip C. Amrein, MD

Blood (2016) 128 (22): 2749.

https://doi.org/10.1182/blood.V128.22.2749.2749

Published: 2016

Journal Articles

Evaluation of Various Strategies to Generate NPM1mut-Specific T Cell Clones

Elke Ruecker-Braun, PhD, Falk Heidenreich, PhD, Cornelia S Link, MD, Maria Schmiedgen, BSc, Rebekka Wehner, PhD, Denise Kühn, BSc, Katharina Heidrich, MD, Nael Alakel, MD, Marc Schmitz, PhD, Christian Thiede, MD, Gerhard Ehninger, MD, Martin Bornhäuser, MD, Johannes Schetelig, MD MSc

Blood (2016) 128 (22): 5718.

https://doi.org/10.1182/blood.V128.22.5718.5718

Published: 2016

NARROW

Global Rnaseq/Proteomic-Phoshoproteomic Analysis Unveil Mir-21 As a Central Player in Driving Th17 Mediated Bone Disease in MM

Targeting T-ALL Cells with Potent Activators of the PP2A Protein Phosphatase Tumor Suppressor

Identification of a Pharmacodynamic Biomarker for SEL24/MEN1703, a First-in-Class Dual PIM/FLT3 Kinase Inhibitor for Acute Myeloid Leukemia, and Its Implementation in the First-in-Human Study CLI24-001

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Selinexor in Combination with Induction and Consolidation Therapy in Older Adults with AML Is Highly Active

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Increased STAT5/STAT3 Intracellular Signaling in Circulating CD34+ Cells of Patients with PMF Correlates with Disease Severity

Concurrent FLT3 Inhibitor and PP2A Activating Drug Treatment Induces Synergistic Cytotoxicity in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication through Proteasomal Degradation of Pim-1 and c-Myc

Tecfidera Modulates Activation of Malignant B-Cells: Correlative Analysis from a Phase 1 Clinical Trial in Patients with Chronic Lymphocytic Leukemia

MiR-193a Is a Negative Regulator of Hematopoietic Stem Cells and Promotes Anti-Leukemic Effects in Acute Myeloid Leukemia

A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (INCB18424-269/AALL1521): Dose-Finding Results from the Part 1 Safety Phase

Interferon-γ Induces Distinct mRNA and Protein Profiles in Acute and Chronic Myeloid Leukemia

Enhanced Efficacy of the SYK Inhibitor Entospletinib and Chemotherapy in Infant Acute Lymphoblastic Leukemia

Integrated Phosphoproteomic and N-Glycoproteomic Landscape of Cutaneous T-Cell Lymphoma Reveals Distinctive Pathogenetic Insights and Therapeutic Vulnerabilities

CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

Mutation-Specific Signaling Profiles and Therapeutic Vulnerabilities of Induced Pluripotent Stem Cell Models of Juvenile Myelomonocytic Leukemia

Characterization of Kinase Activity By Phosphoproteomics in Myeloid Cell Lines for Identification of Driving Oncogenic Pathways

DNA Damaging Agents Cause a Sub-Cellular Re-Localisation of Nucleophosmin in an npm1 Mutated Acute Myeloid Leukemia (AML) Cell Line and in Primary AML Cells Carrying an npm1 Mutation

Examination of Phosphoprotein Targets in Timed Samples from Patients with RAS -Mutated AML during Concurrent Treatment with Alpelisib and Binimetinib on the Phase Ib Clinical Trial CMEK162X2109

Evaluation of Various Strategies to Generate NPM1mut-Specific T Cell Clones

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only